A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors
- PMID: 17560915
- DOI: 10.1016/j.amjsurg.2006.11.025
A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors
Abstract
Background: Surgical resection is the only potentially curative approach for patients with primary and metastatic liver tumors. Unfortunately, most patients with hepatic malignancy are precluded from resection due to multifocal disease, anatomic limitations, inadequate functional liver reserve, extrahepatic metastases, or medical comorbidities. Consequently, several methods of tumor ablation have been developed as alternate treatment strategies for patients with unresectable hepatic tumors or as adjuncts in total cancer therapy. The purpose of this review is to inclusively define the various ablation modalities available (transarterial, chemical, and thermal ablative), and to describe the procedures, general applications, and reported outcomes.
Data sources: A MEDLINE and CINAHL search of the English-language literature was performed on transarterial, chemical, and thermal ablative therapies.
Conclusions: Presently, radiofrequency thermal ablation is the most widely applicable liver-directed modality for hepatic tumor ablation, enabling treatment of primary and metastatic tumors. However, other transarterial and thermoablative techniques are available with accumulating data for their use. Lacking at present are studies that define the role and potential benefit of the various liver-directed modalities in the treatment algorithm for hepatic tumors.
Similar articles
-
The role of focal liver ablation in the treatment of unresectable primary and secondary malignant liver tumors.Semin Radiat Oncol. 2005 Oct;15(4):265-72. doi: 10.1016/j.semradonc.2005.04.004. Semin Radiat Oncol. 2005. PMID: 16183480 Review.
-
Transcatheter and ablative therapeutic approaches for solid malignancies.J Clin Oncol. 2007 Mar 10;25(8):978-86. doi: 10.1200/JCO.2006.09.8657. J Clin Oncol. 2007. PMID: 17350947 Review.
-
Liver-directed treatment modalities for primary and secondary hepatic tumors.Surg Clin North Am. 2009 Feb;89(1):97-113, ix. doi: 10.1016/j.suc.2008.10.004. Surg Clin North Am. 2009. PMID: 19186233 Review.
-
Interventional treatments for hepatocellular carcinoma.Hepatobiliary Pancreat Dis Int. 2006 Nov;5(4):495-500. Hepatobiliary Pancreat Dis Int. 2006. PMID: 17085331 Review.
-
Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM).Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S64-75. doi: 10.1016/j.ejso.2007.09.027. Epub 2007 Dec 3. Eur J Surg Oncol. 2007. PMID: 18061390 Review.
Cited by
-
Therapy options for treatment of hepatic malignancy.Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1824-6. doi: 10.1007/s00259-008-0798-x. Eur J Nucl Med Mol Imaging. 2008. PMID: 18536915 No abstract available.
-
Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases.Cochrane Database Syst Rev. 2009 Apr 15;2009(2):CD007060. doi: 10.1002/14651858.CD007060.pub2. Cochrane Database Syst Rev. 2009. PMID: 19370671 Free PMC article.
-
Is percutaneous ethanol injection therapy still effective for hepatocellular carcinoma in the era of radiofrequency ablation?Gut Liver. 2010 Sep;4 Suppl 1(Suppl 1):S105-12. doi: 10.5009/gnl.2010.4.S1.S105. Epub 2010 Sep 10. Gut Liver. 2010. PMID: 21103288 Free PMC article.
-
Novel laparoscopic bipolar radiofrequency energy technology for expedited hepatic tumour ablation.HPB (Oxford). 2009 Mar;11(2):135-9. doi: 10.1111/j.1477-2574.2008.00024.x. HPB (Oxford). 2009. PMID: 19590637 Free PMC article.
-
Colorectal liver metastases; the current scenario.Indian J Surg Oncol. 2010 Dec;1(4):350-5. doi: 10.1007/s13193-011-0066-6. Epub 2011 Apr 19. Indian J Surg Oncol. 2010. PMID: 22693391 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical